286 件 ・ 関連度順
概要と使いどころ
Converts biomedical table content into clear manuscript or presentation narrative by prioritizing meaningful patterns, contrasts, and interpretation boundaries rather than restating every number.
日本語の概要は準備中です。原文の説明を表示しています。
Write code evaluators for known failure modes with objective rules. Use when code can check the rule from a trace, with or without a reference answer. Use `write-judge-prompt` when the rule requires interpretation.
日本語の概要は準備中です。原文の説明を表示しています。
Design LLM-as-Judge evaluators for subjective criteria that code-based checks cannot handle. Use when a failure mode requires interpretation (tone, faithfulness, relevance, completeness). Do NOT use when the failure mode can be checked with code (regex, schema validation, execution tests); use `write-code-eval`. To validate an existing judge, use `validate-evaluator`.
日本語の概要は準備中です。原文の説明を表示しています。
Design statistically rigorous A/B tests for product features, UI changes, onboarding flows, and pricing experiments. Use when asked to set up an experiment, design an A/B test, calculate sample size, or interpret test results. Produces a complete test plan with hypothesis, variant definitions, sample size, duration estimate, guardrail metrics, and a results interpretation guide.
日本語の概要は準備中です。原文の説明を表示しています。
Runs JACKS (Joint Analysis of CRISPR/Cas9 Knockout Screens; Allen et al 2019 Genome Research) which models per-sgRNA log-fold-change as the product of a treatment-dependent gene-essentiality term and a treatment-independent guide-efficacy term. Covers the Bayesian decomposition math, the hierarchical efficacy prior shared across screens performed with the same library, when JACKS outperforms MAGeCK (multi-screen joint analysis, libraries with broad efficacy variance) and when it does not (single screen, novel libraries with no prior efficacy), library-reuse efficacy transfer, downstream essentiality interpretation, and the 2.5x sample-size reduction enabled by efficacy-aware testing. Use when running multiple screens with the same library, when guide-level noise is suspected to dominate per-gene signal, when reusing published essentiality reference screens for efficacy priors, or when comparing screens performed across cell lines that share library but differ biologically.
日本語の概要は準備中です。原文の説明を表示しています。
Creates DE-specific diagnostic and result visualizations using DESeq2/edgeR built-in functions and lightweight ggplot2 wrappers. Covers MA plot (with the shrunken-LFC compression effect), volcano (with the apeglm caveat that p-values are unchanged), PCA on VST/rlog (never raw counts), sample distance heatmaps, top-DE-gene heatmaps with the row-scaling trap, dispersion / BCV plot interpretation, p-value histogram diagnostics, plotCounts for individual genes, blind=TRUE vs FALSE rationale, and the n=3 visualization stake. Use when generating DE diagnostic plots, choosing VST vs rlog for visualization, troubleshooting suspicious plot patterns (shifted MA cloud, batch-dominated PCA, anti-conservative p-value histogram), or building a standard QC figure panel.
日本語の概要は準備中です。原文の説明を表示しています。
Predict RBP binding from RNA sequence using deep learning models (RBPNet sequence-to-signal, RNAProt RNN, GraphProt2 GCN with structure, DeepCLIP, DeepRiPe multi-modal CNN) for variant-effect prediction, in silico binding-site discovery, model interpretation, and transfer learning from CLIP and RBNS datasets. Use when computational prediction of RBP binding from sequence is needed, evaluating variant effects on binding without further wet-lab experiments, comparing model performance, or training a custom model on ENCODE eCLIP data.
日本語の概要は準備中です。原文の説明を表示しています。
Quantifies CRISPR editing outcomes with CRISPResso2 (Clement 2019 Nat Biotechnol) across Cas9-nuclease (indels, HDR), CBE and ABE base editors (target conversion + bystander), and prime editor (pegRNA-templated) modes. Covers single-amplicon (CRISPResso), multi-sample batch (CRISPRessoBatch), pooled-amplicon (CRISPRessoPooled), WGS off-target (CRISPRessoWGS), and sample-comparison (CRISPRessoCompare) workflows; quantification-window math that controls what is called edited; substitution-vs-indel diagnostic to distinguish BE from Cas9 contamination; MMEJ deletion pattern interpretation; allele-frequency tables; and failure modes from amplicon misalignment or contamination. Use when quantifying editing from amplicon sequencing, choosing CRISPResso mode by design, distinguishing intended edits from bystanders and indel byproducts, debugging low-alignment runs, or generating publication-grade editing reports.
日本語の概要は準備中です。原文の説明を表示しています。
Designs and analyzes combinatorial CRISPR screens covering paired-Cas9 (Big Papi, Najm 2018), enhanced AsCas12a multiplex (enCas12a, DeWeirdt 2021), in4mer 4-guide-array Cas12a (Esmaeili Anvar N et al 2024 Nat Commun 15:3577) and the Inzolia paralog-pair library, paralog-buffering detection (Dede 2020 Genome Biol; Thompson 2021 Nat Commun 12:1302), genetic-interaction (GI) scoring as observed_double_LFC minus expected_additive_double_LFC, synthetic-lethal and synthetic-rescue interaction interpretation, the half-of-essentiality buffered by paralogs phenomenon, multiplex screen statistical analysis with MAGeCK MLE interaction terms, and the relationship to single-cell combinatorial Perturb-seq. Use when designing a paralog or pathway-pair screen, choosing between paired-Cas9 (Big Papi) and Cas12a multiplex (Inzolia), interpreting genetic interaction scores, identifying synthetic-lethal targets for drug development, or scaling beyond single-gene CRISPR screens.
日本語の概要は準備中です。原文の説明を表示しています。
Analyzes base-editing screens for variant function. Covers library design (Hanna 2021 ClinVar-scale CBE screen benchmarked on BRCA1/2, Cuella-Martin 2021 DDR saturation), CBE vs ABE chemistry choice (BE3/BE4 vs ABE7.10/ABE8.20/ABE8e), editing-window math (positions 4-8 from PAM-distal end; 4-7 for ABE7.10), bystander-edit quantification and the variant-call ambiguity it creates, sgRNA-efficiency filtering before hit calling, indel byproduct interpretation, the substitution-vs-indel diagnostic, variant annotation against ClinVar / COSMIC, and the Broad be-validation-pipeline. Use when designing a BE variant screen, choosing CBE vs ABE for a specific edit, interpreting bystander-confounded hits, distinguishing functional signal from indel artifact, integrating CRISPResso2 output with screen scoring, or deciding BE vs PE for SNV installation.
日本語の概要は準備中です。原文の説明を表示しています。
Classify constitutional (germline) copy number variants for clinical reporting using the 2019 ACMG/ClinGen technical standards points-based framework, with ClassifyCNV and AnnotSV for semi-automated scoring. Covers the separate copy-number-loss and copy-number-gain rubrics, the five-tier classification, ClinGen haploinsufficiency/triplosensitivity and dosage-sensitive regions, de novo and segregation evidence, and population-frequency benign evidence. Use when assigning pathogenic/likely-pathogenic/VUS/likely-benign/benign to a constitutional CNV, scoring a CNV against ACMG/ClinGen criteria, or distinguishing the automatable evidence from the case-specific evidence requiring manual input.
日本語の概要は準備中です。原文の説明を表示しています。
Queries gnomAD v4 (807k samples), v3, v2.1.1, and constraint metrics with grpmax FAF95, bottleneck-group exclusion, LOEUF interpretation, SV/CNV/mtDNA catalogs, and Whiffin max-credible-AF framework. Use when filtering rare variants, applying ACMG BS1/BA1, ranking genes by LoF intolerance, or selecting between v2 (GRCh37 + chrX/Y constraint) and v4 (GRCh38 + 807k samples).
日本語の概要は準備中です。原文の説明を表示しています。
Predicts whether a DNA variant alters mRNA splicing using sequence-based deep-learning tools — SpliceAI (10kb context dilated CNN, clinical default), Pangolin (multi-tissue), MMSplice (modular per-region CNN with calibrated ΔPSI), SpliceTransformer/TrASPr (tissue-aware transformers), SpliceVault (empirical 300K-RNA lookup of likely mis-splicing outcomes), CADD-Splice (composite score). Applies the ClinGen SVI 2023 framework for ACMG/AMP variant interpretation (PVS1, PP3, BP4 evidence codes), HGVS splicing nomenclature (c.123+1G>A, c.123-3T>G, r.spl?), extended-window scoring for deep-intronic pseudoexons, tissue-specific predictions, branchpoint variant detection (BPHunter, LaBranchoR), and splice-switching ASO design. Use when interpreting splice impact of clinical variants, prioritizing VUS, identifying deep-intronic pathogenic variants, or designing ASOs.
日本語の概要は準備中です。原文の説明を表示しています。
AIOps-style CloudBase inspection skill (v3). Use when users need health checks, log diagnosis, alarm interpretation (CPU alert normal?, peak QPS), metrics via queryEnv(action=metrics), or fault playbooks for 429 / function 404 / ACCESS_TOKEN_INVALID / zero invocations. Triggers on 巡检, 诊断, 告警, 峰值 QPS, 限频, 调用量为 0, troubleshooting.
日本語の概要は準備中です。原文の説明を表示しています。
Draft submission-ready mathematical-modeling paper sections from the approved solution package, frozen numbers, human decision ledger, and verified figures without searching scattered exploratory outputs or inventing interpretation.
日本語の概要は準備中です。原文の説明を表示しています。
Run conversion rate optimization through hypothesis-driven testing including audit, hypothesis generation, test design, statistical analysis, and rollout decisions. Use this skill whenever the user wants to optimize conversion, run A/B tests, audit a funnel, generate test hypotheses, design experiments, or analyze test results. Triggers on conversion optimization, CRO, A/B test, split test, multivariate test, hypothesis, conversion funnel, funnel audit, experiment design, statistical significance, lift, optimization. Also triggers when the user has a conversion problem and isn't sure where to start, or when test results are ambiguous and need interpretation.
日本語の概要は準備中です。原文の説明を表示しています。
How to read experiment results without fooling yourself. Confidence intervals, p-values, multiple testing, sequential testing, CUPED, heterogeneous treatment effects, ratio metrics, network effects, dashboard reconciliation, and the interpretation failures that produce confidently wrong shipping decisions. Use this skill whenever the user is reading a finished experiment result panel and about to make a ship, kill, or iterate decision, or when an experiment number does not match the dashboard number. Triggers on read experiment results, result panel, ship or kill decision, p-value, confidence interval, statistical significance, multiple testing, peeking, sequential testing, CUPED, variance reduction, heterogeneous treatment effects, ratio metric, network effects, inconclusive test, experiment versus dashboard mismatch. Use `experiment-design` instead when the test has not run yet and the question is hypothesis, sample size, duration, or what to test.
日本語の概要は準備中です。原文の説明を表示しています。
Slow down interpretation from observation to action. Use when students or adults need to examine assumptions in conflict, dialogue, or inquiry.
日本語の概要は準備中です。原文の説明を表示しています。
omicsViewer visualizes ExpressionSet (or SummarizedExperiment) in an interactive way. The omicsViewer has a separate back- and front-end. In the back-end, users need to prepare an ExpressionSet that contains all the necessary information for the downstream data interpretation. Some extra requirements on the headers of phenotype data or feature data are imposed so that the provided information can be clearly recognized by the front-end, at the same time, keep a minimum modification on the existin
日本語の概要は準備中です。原文の説明を表示しています。
Implements miscellaneous functions for interpretation of single-cell RNA-seq data. Methods are provided for assignment of cell cycle phase, detection of highly variable and significantly correlated genes, identification of marker genes, and
日本語の概要は準備中です。原文の説明を表示しています。
This package enables the interpretation and analysis of results from a gene set enrichment analysis using network-based and text-mining approaches. Most enrichment analyses result in large lists of significant gene sets that are difficult to interpret. Tools in this package help build a similarity-based network of significant gene sets from a gene set enrichment analysis that can then be investigated for their biological function using text-mining approaches.
日本語の概要は準備中です。原文の説明を表示しています。
ASURAT is a software for single-cell data analysis. Using ASURAT, one can simultaneously perform unsupervised clustering and biological interpretation in terms of cell type, disease, biological process, and signaling pathway activity. Inputting a single-cell RNA-seq data and knowledge-based databases, such as Cell Ontology, Gene Ontology, KEGG, etc., ASURAT transforms gene expression tables into original multivariate tables, termed sign-by-sample matrices (SSMs).
日本語の概要は準備中です。原文の説明を表示しています。
Reactome is a free, open-source, curated and peer-reviewed pathway database. Their goal is to provide intuitive bioinformatics tools for the visualization, interpretation and analysis of pathway knowledge.
日本語の概要は準備中です。原文の説明を表示しています。
Beta testing strategy for iOS/macOS apps. Covers TestFlight program setup, beta tester recruitment, feedback collection methodology, user interviews, signal-vs-noise interpretation, and go/no-go launch readiness decisions. Use when planning a beta, setting up TestFlight, collecting user feedback, or deciding if ready to launch.
日本語の概要は準備中です。原文の説明を表示しています。